Symbols

CDXS

Codexis·NASDAQ

--(--)

CDXS fundamentals

CDXS Q4 2025 Earnings

Codexis (CDXS) released its earnings on Mar 11, 2026: revenue was 38.91M (YoY +81.34%), beat estimates; EPS was 0.11 (YoY +184.62%), beat estimates.

Revenue / YoY

38.91M

+81.34%

EPS / YoY

0.11

+184.62%

Report date

Mar 11, 2026

CDXS Earnings Call Summary for Q4,2025

Breakthrough Manufacturing: 10g siRNA synthesis milestone validates ECO platform, with 3kg client production achieved.
Partnership Surge: 3 CDMO agreements signed, 55 pipeline opportunities highlight industry shift to enzymatic synthesis.
Innovative Stereocontrol: 2026 data will show if stereoisomer control improves drug potency, creating new revenue streams.
Financial Strength: $78M cash balance, stable 64% gross margin, 2026 revenue guidance of $72-76M reflects cautious optimism.
Growth Catalysts: GMP facility expansion, Merck tech transfer deal, and late-stage biocatalysis pipeline support near-term stability.

Earnings

EPS

Revenue

Revenue & Expenses

CDXS has released its 2025 Q4 earnings report, with revenue of 38.91M, reflecting a YoY change of 81.34%, and net profit of 9.60M, showing a YoY change of 192.53%. The Sankey diagram below clearly presents CDXS's revenue sources and cost distribution.

Key Indicators

Codexis (CDXS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Codexis (CDXS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Codexis (CDXS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Codexis (CDXS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown